Abstract 180P
Background
Immune checkpoint inhibitors (ICI) have shown limited efficacy in high-grade serous carcinomas (HGSC). The NeoPembrOv randomized phase II trial investigated the combination of Pembrolizumab (P) with NeoAdjuvant ChemoTherapy (NACT), providing an opportunity to identify resistance mechanisms.
Methods
Patients (n=91) were randomized 2:1 to NACT+P or NACT. Paired samples were analyzed using RNA-seq (n=53) and multiplexed immunofluorescence staining (n=64) for CD8, PD-1, ActCasp3, panCK, CD31, and VEGFR2. Immune and endothelial signatures were assessed using MCP-counter and quanTIseq algorithms. Cell densities and nearest neighbors were determined based on InForm software output. We investigated the impact of NACT±P on the tumor microenvironment and identified parameters associated with survival. As no transcriptomic dataset of HGSC patients under ICI was available, we used an external validation cohort of 102 head and neck cancer patients.
Results
Analysis of DEG revealed a significant enrichment of T cell activation/differentiation pathways in the NACT+P arm only after treatment. We showed a significant increase in CD8+PD-1+ T cells density in tumor islets in the NACT+P arm compared to NACT (p=0.015). This increase observed in 15% of cases (n=6/41) was associated with improved overall survival (OS) (LR test, p=0.01).The median distance between apoptotic tumor and the nearest CD8+PD-1+ cell significantly decreased after NACT+P. Univariate cox models revealed a negative association between the MCP-counter endothelial cell signature and survival (HR=1.97, 95% CI [1.10-3.49], p=0.02) in the NACT+P arm, with a significant interaction with treatment arm (p=0.046). In situ analysis confirmed the negative predictive impact of high expression of VEGFR2 on CD31+ endothelial cells in patients receiving NACT+P, significantly affecting OS (p=0.005). KDR expression (VEGFR2) was validated as a predictive biomarker in an external cohort for OS (p=0.044).
Conclusions
Only a subset of HGSC patients can benefit from ICI. Targeting VEGFR2+ endothelial cells may overcome resistance. Clinical trials using VEGFR2 inhibitors are warranted.
Clinical trial identification
NCT03275506.
Legal entity responsible for the study
Arcagy-Gineco.
Funding
ARC Foundation.
Disclosure
O. Le Saux: Financial Interests, Personal, Advisory Board: Novartis, MSD, GSK; Financial Interests, Personal, Invited Speaker: Lilly, AstraZeneca, Clovis; Financial Interests, Institutional, Trial Chair: Novartis, Hospira-Pfizer foundation, Astellas. E. Coquan: Financial Interests, Personal, Advisory Board: Sanofi, MSD, BMS, Ipsen, AstraZeneca. I.L. Ray-Coquard: Financial Interests, Personal, Advisory Board: Roche, GSK, AstraZeneca, Mersana, Deciphera, Amgen, Oxnea, Merck Sereno, Agenus, Novartis, Macrogenics, Clovis, EQRX, Adaptimmune, Eisai, SUTRO, BMS, Adaptimmune, Daiichi Sankyo; Financial Interests, Institutional, Other, COLIBRI translational research: BMS; Financial Interests, Institutional, Advisory Board, translational research NEOPREMBROV trial: MSD; Non-Financial Interests, Personal, Principal Investigator: PAOLA1; Non-Financial Interests, Personal, Other, President: Gineco. All other authors have declared no conflicts of interest.
Resources from the same session
35P - Peripheral immunotype classification for monitoring Soft Tissue Sarcoma patients
Presenter: Jani Sofia Almeida
Session: Poster Display
36P - Expression of germinal center B cell- and Th17 cell-related transcripts are prognostic of soft-tissue sarcoma patient outcomes
Presenter: Giulia Petroni
Session: Poster Display
38P - Machine learning-based pathomics model to predict the infiltration of Treg and prognosis in IDH-wt GBM
Presenter: Shaoli Peng
Session: Poster Display
40P - The role of low avidity tumour-specific CD8+ T cells in immunotherapeutic response to anti-PD-1
Presenter: Doreen Lau
Session: Poster Display
41P - Contrasting drivers of response to immunotherapy across solid tumour types: results from analysis of >2500 cases
Presenter: Danwen Qian
Session: Poster Display
42P - TCCIA: A Comprehensive Resource for Exploring CircRNA in Cancer Immunotherapy
Presenter: Jian-Guo Zhou
Session: Poster Display
43P - Immune and tumor cells expression of VISTA in a panel of cancer indications: A strategy to inform selection of patients treated with anti-VISTA
Presenter: Pierre Launay
Session: Poster Display
44P - Exploratory Analysis of Peripheral Pharmacodynamic (PD) Biomarkers After Sitravatinib (Sitra) and Tislelizumab (TIS) in Advanced Solid Tumors: SAFFRON-103
Presenter: Yi-Long Wu
Session: Poster Display
45P - Protein biomarkers associated with organ-specific immune-related toxicity and response to management identified by proteome analysis of extracellular vesicles from plasma
Presenter: Anders Kverneland
Session: Poster Display